COCP Cocrystal Pharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1412486 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-17.2%
TTM EPS YoY18.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-219.1%
ROA-131.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets60.5%
Debt / equity0.00x
Current ratio1.72x
Interest coverage122.45x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-28.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $105,000 | $105,000 | $225,000 | — | — | — | — | — |
| R&D expense | $1.98M | $2.14M | $1.37M | $1.62M | $954,000 | $1.12M | $1.36M | $2.04M |
| SG&A expense | $1.62M | $1.15M | $1.21M | $862,000 | $1.14M | $986,000 | $981,000 | $1.19M |
| Operating income | -$3.49M | -$3.18M | -$2.36M | -$2.48M | -$2.09M | -$2.11M | -$2.34M | -$3.23M |
| Interest expense | -$15,000 | -$10,000 | -$22,000 | -$47,000 | -$22,000 | -$28,000 | -$37,000 | -$55,000 |
| Income tax | $0 | $0 | $0 | — | — | — | — | — |
| Net income | -$3.44M | -$3.16M | -$2.30M | -$2.43M | -$2.05M | -$2.06M | -$2.30M | -$3.27M |
| EBITDA | -$3.48M | -$3.17M | -$2.34M | -$2.47M | -$2.08M | -$2.09M | -$2.32M | -$3.20M |
| EPS (basic) | -0.20 | -0.23 | -0.17 | — | -0.19 | -0.20 | -0.23 | — |
| EPS (diluted) | -0.20 | -0.23 | -0.17 | — | -0.19 | -0.20 | -0.23 | — |
| Weighted avg. shares (diluted) | 17.42M | 13.79M | 13.79M | — | 10.99M | 10.17M | 10.17M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.87M | $2.17M | $4.68M | $7.03M | $7.73M | $4.77M | $6.92M | $9.86M |
| Current assets | $5.51M | $3.24M | $5.94M | $8.13M | $8.78M | $6.76M | $8.83M | $11.58M |
| PP&E, net | $59,000 | $69,000 | $81,000 | $93,000 | $106,000 | $107,000 | $127,000 | $153,000 |
| Total assets | $6.77M | $4.65M | $7.43M | $9.71M | $10.45M | $8.51M | $10.66M | $13.46M |
| Current liabilities | $3.20M | $2.62M | $2.23M | $2.21M | $1.52M | $1.83M | $1.93M | $2.43M |
| Total liabilities | $4.10M | $3.60M | $3.31M | $3.38M | $2.78M | $3.17M | $3.35M | $3.93M |
| Shareholders' equity | $2.67M | $1.04M | $4.12M | $6.33M | $7.67M | $5.33M | $7.30M | $9.52M |
| Shares outstanding | 19.26M | 13.79M | 13.79M | 13.78M | 13.04M | 10.17M | 10.17M | 10.17M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.30M | -$2.52M | -$2.34M | -$1.74M | -$1.36M | -$2.15M | -$2.94M | -$3.16M |
| Capital expenditure | — | — | — | $0 | — | — | — | $0 |
| Free cash flow | — | — | — | -$1.74M | — | — | — | -$3.16M |
| Investing cash flow | — | — | — | $0 | — | — | — | $0 |
| Financing cash flow | — | — | — | $1.03M | — | — | — | — |
| Depreciation & amortization | $10,000 | $12,000 | $12,000 | $13,000 | $13,000 | $21,000 | $25,000 | $28,000 |
| Stock-based compensation | $74,000 | $92,000 | $84,000 | $56,000 | $48,000 | $84,000 | $82,000 | $85,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.